Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463692 | 0.78 | PDPK1 (0.36) | PARP1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL14912198 | 0.72 | MAPT (0.53) | ALDH1A1MAPT | |
| SCHEMBL3535354 | 0.68 | PDPK1 (0.34) | PARP1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL4507655 | 0.68 | PDPK1 (0.34) | PARP1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL32691553 | 0.68 | PARP1 (0.53) | PARP1ALDH1A1 | |
| SCHEMBL14911621 | 0.67 | SLC2A1 (0.38) | PARP1ALDH1A1 | |
| SCHEMBL16611233 | 0.65 | PARP1 (0.41) | PARP1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL162330 | 0.64 | — | — | |
| SCHEMBL3117561 | 0.64 | JAK2 (0.61) | PARP1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL24757248 | 0.63 | JAK2 (0.42) | PARP1JAK2RPS6KA3MELKSTK24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| WO-2024208315-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-10-10 | — | — | WO | disclosed |
| WO-2023109120-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023108536-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023108536-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-108137497-B | Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-15 | — | — | CN | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-20080182868-A1 | Novel chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1620094-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| WO-2004100947-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182868-A1 | Novel chemical compounds | HRAS, VHL, TP53 | PARP1 1118/4885JAK2 258/4885RPS6KA3 355/4885 |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PARP1 3415/4885JAK2 2963/4885RPS6KA3 815/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | PARP1 1819/4885JAK2 26/4885RPS6KA3 252/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PARP1 3415/4885JAK2 2963/4885RPS6KA3 815/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PARP1 1461/4885JAK2 49/4885RPS6KA3 355/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PARP1 1461/4885JAK2 49/4885RPS6KA3 355/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PARP1 3415/4885JAK2 2963/4885RPS6KA3 815/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PARP1 3415/4885JAK2 2963/4885RPS6KA3 815/4885 |
| US-20070161672-A1 | Compounds | KCNJ2, KCNT1, KCNT2 | PARP1 1053/4885JAK2 639/4885RPS6KA3 1916/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | PARP1 1461/4885JAK2 49/4885RPS6KA3 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.